Here ya go Foose. Some news effecting us. Just passed (last week) Defense Authorization Act (DAA) brings us glad tidings! Something to build from.
Kind of. A little convoluted. LineaRX client TYME. Here's how we're tied in:
Cancer research has been listed for funding under the Recalcitrant Cancer passage in the DAA, where five difficult cancers have been been specifically covered since 2013: Quote: Recalcitrant Cancer Research Act of 2012 (2012; 112th ...https://www.govtrack.us › congress › bills To provide for scientific frameworks with respect to recalcitrant cancers. ... Provisions of this bill were incorporated into other bills which were enacted. This bill was ... H.R. 4310: National Defense Authorization Act for Fiscal Year 2013. Enacted ... Big day in PANCAN when RECALCITRANT PASSAGE added in defense bill.
Been going for six years without much change. This year's DAA passage is like a homer out of the park.
Here's a link to PANCAN's sign up page for the clinical trials for SM 88 efficacy all over the US And the LINK
With the 250 patients, and our 3000 Vitatek kits (3000 ÷ 250 = 12) I expect we'll have monthly reports on the efficacy of our kit and the SM88 cancer therapy.